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A B S T R A C T
Background: Patients with methamphetamine (MA) abuse under methadone maintenance treatment (MMT) are
susceptible to several complications including cognitive disturbance and mental health disorder. This trial was
designed to determine the impacts of quetiapine administration on cognitive function and mental health scale in
patients with MA abuse under MMT.
Methods: This study was carried out in 60 MA abusers under MMT. Patients were randomly allocated to receive
either 100mg quetiapine (n=30) or control (n=30) daily for 8 weeks. Cognitive function and mental health
scale were taken at baseline and post-treatment to evaluate relevant variables.
Results: Quetiapine signiﬁcantly decreased depression (b -3.94; 95% CI, -7.73, -0.16; P=0.04) and sleep dis-
order (b -2.18; 95% CI, -2.89, -1.47; P < 0.001). Also, quetiapine administration resulted in a signiﬁcant re-
duction in Iowa Gambling Task (b -2.70; 95% CI, -4.69, -0.71; P=0.009), and signiﬁcant increases in Verbal
Fluency Test (b 3.04; 95% CI, 1.24, 4.85; P=0.001), Reverse Digit Span (b 2.80; 95% CI, 2.13, 3.47; P=0.001)
compared with the placebo.
Conclusion: Overall, taking 100mg quetiapine daily for 8 weeks by patients MA abuse in MMT had favorable
eﬀects on some of cognitive functions and mental health parameters.
1. Introduction
methamphetamine (MA) is a psycho-stimulant drug with highly
addictive characteristics (Ghaderi et al., 2017b; Mehrjerdi et al., 2014).
Recently, MA abuse has become a health concern in the Iranian po-
pulation (Massah and Moradi, 2018). Research ﬁndings demonstrated
that recent years, the MA abuse increased from 3.9% to 89.5% among
women and 60.3% among men in Iran (Alammehrjerdi et al., 2018).
MMT improves social functioning and quality of life (Dolan et al.,
2003). However, despite the extensive and successful implementation
of the MMT, many challenges and obstacles remain. Recently, MA de-
pendence increased among patients under MMT (Noori et al., 2016).
The MA dependence enhance trend over time which may provide a lack
of consideration to untreated MA dependence in the cases with MMT
(Alammehrjerdi et al., 2018). This problem due to self-treatment for
mental health dysfunction in patients under MMT (Alam Mehrjerdi
et al., 2013; Ghaderi et al., 2018; Massah and Moradi, 2018). Patients
MA abuse under MMT have some psychiatric problems such as cogni-
tive impairment (Potvin et al., 2018; Wang et al., 2017), depression and
anxiety symptoms (Glasner-Edwards et al., 2009, 2010) and sleep dis-
turbances (Ghaderi et al., 2017a; Mahoney et al., 2014). Recently,
various psychosocial interventions (e.g., technology-based treatments,
Matrix Model and cognitive- behavioral therapy) have been employed
in the treatment of cases with MA dependence (Minozzi et al., 2016;
Tait et al., 2015). Despite several attempts, there is no the approved
pharmacotherapy platform for MA dependence therapy yet
(Phillips et al., 2014).
Quetiapine, a new antipsychotic drug, has associated with favorable
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eﬀects on negative and positive symptoms, and cognitive disturbance in
chronic schizophrenia (Purdon et al., 2001). Some researches docu-
mented that quetiapine may reduce the anxiety score and improve sleep
quality (Kapur et al., 2000), cognitive impairment and depression
symptoms (Baune, 2008). Several studies showed the favorable eﬀects
of quetiapine on mental health, and cognitive function. In the study by
Sattar et al. (2004), it was documented that consuming 50mg/day to a
maximum of 300mg/day quetiapine (average 153mg/day) for 28 day
in patients with coexisting substance dependence disorders had favor-
able eﬀects on sleep, anxiety. Also, previous studies showed that que-
tiapine intake at a dosage of 50–100mg/day to people with bipolar
disorder and cocaine dependence had beneﬁcial eﬀects on psychiatric
symptoms (Brown et al., 2002). In addition, recently studies demon-
strated that administration of quetiapine improves verbal short-term
memory, inhibition abilities and positive parameters in patients psy-
chosis (Urben et al., 2012), and memory in animal models (He et al.,
2006). However, quetiapine compared to olanzapine did not improve
learning, memory, attention and working memory or cognitive func-
tions in an adolescent population (Robles et al., 2011).
Quetiapine is known as an atypical neuroleptic and D2 antagonism.
It has been showed that this drug has a high aﬃnity for serotonin,
histamine and α1-adrenergic receptors, while has a low aﬃnity for
dopamine receptors (Kondo et al., 2013). It has been showed that
quetiapine exerts its roles via decreasing of dopamine blockade, which
could result in the reduction of drug abuse. Moreover, the dopamine
receptors could be blocked by quetiapine in the limbic system that lead
to improvement of minimal blockade role of dopamine in the reward
system. Subsequently, quetiapine enables to bind to histamine H1 re-
ceptors and induction relaxation, which can also enhance the cognitive
function and mental health (Purdon et al., 2001; Samiei et al., 2016;
Sattar et al., 2004). Despite the well known therapeutic eﬀects of
quetiapine, the impacts of quetiapine on cognitive function, depression
and anxiety in cases with MA abuse under MMT are restricted. We
considered that the utilization of quetiapine in patients with MA abuse
under MMT might be provided for elevating the quality of life and re-
ducing the side eﬀects. Thus, in the current research, the eﬀects of
quetiapine intake on mental features including cognitive function and
mental health in MA abuse under MMT cases were assessed.
2. Methods
2.1. Trial design
This study was registered in the Iranian website for registration of
clinical trials at http://www.irct.ir: IRCT20171106037290N1,
the Primary Registry in the WHO Registry Network set up in colla-
boration with Ministry of Health and Medical Education. This study was
conducted among 60 MA abuse under MMT, aged 18–65 years who
were referred to the Golabchi Clinic in Kashan, Iran. The research ethics
committee of Medical Science department at Kashan University esti-
mated and approved the study protocol (IR.Kaums.REC.1396.123). This
scientiﬁc experiment was carried out in accordance with the
Declaration of Helsinki. All participants ﬁled their agreement to take
part in this study. All consent forms were reviewed by the research
ethics committee of Medical Science department at Kashan University.
Fig. 1. Summary of patient ﬂow.
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2.2. Inclusion criteria
The included subjects were aged 18–65 years, with history of MA
and opioid co-abuse in the past year and currently undergoing metha-
done maintenance treatment, evaluated by the drug abuse section of the
Structured Clinical Interview for DSM-IV, Seeking treatment for MA
abuse.
2.3. Exclusion criteria
The excluded subjects were suicide eﬀorts history within the past
one years or either psychotic scale in the past 24 weeks or suicidal
ideations as considered, cocaine and major cardiovascular disturbance,
alcohol dependence, metabolic diseases (e.g., neurological diseases and
diabetes).
2.4. Study design
Participation were randomized into both groups and received either
100mg quetiapine (Tadbir Kala Jam trading Company, Tehran, Iran) or
placebo (Barij Essence, Kashan, Iran) (n=30 each group) daily for 8
weeks. The lack of document on the suitable dosage of quetiapine in
treatment of MA and opioid co-abuse resulted in we employed the
above-stated dosage of quetiapine based on a recently published report
in subjects with cocaine dependence and bipolar disorder (Brown et al.,
2002; Telles-Correia et al., 2017). The dosage form of administered
methadone was syrup. All patients completed three physical activity
and 3-day food records as metabolic equivalents (METs)
(Ainsworth et al., 2000) at weeks 0, 2, 4, 6 and 8 of the intervention.
2.5. Blinding
Placebo and quetiapine tablets were made in the same way. These
tablets had identical shape, size, color, texture, and odor. Placebo
quetiapine tablets were obtained in the same container with a code
numeral. The tablets were made by Zahravi, Tabriz, Iran. Hence, par-
ticipation, physician, and other agents were all blind to the intervention
group assignments.
2.6. Randomization
Randomization assignment was accomplished using computer-gen-
erated random numbers and was done by a trained staﬀ at the clinic as
blindness.
2.7. Safety
The included subjects were invited to tell agents about all side-ef-
fects during the intervention. The clinical signs were considered and
assessed at the initiation and at each base-line visit. Moreover, potential
complaints were considered with telephone call every day and the
physician and psychiatrists were responsible for discontinuing or con-
tinuing the taking tablets.
Table 1
General characteristics of the study participantsa.
Placebo group Quetiapine group Pb
(n=28) (n=28)
Age (y) 38.7 ± 10.0 37.1 ± 9.0 0.68
Height (cm) 169.2 ± 7.5 170.6 ± 6.5 0.14
Weight at study baseline (kg) 74.8 ± 11.9 74.4 ± 11.7 0.38
Weight at the end-of-trial (kg) 72.1 ± 10.5 72.3 ± 9.2 0.46
Weight change (kg) -0.39 ± 2.1 0.14 ± 2.5 0.40
BMI at study baseline (kg/m2) 26.2 ± 4.2 24.8 ± 3.5 0.18
BMI at the end-of-trial (kg/m2) 26.0 ± 4.2 24.8 ± 3.1 0.23
BMI change (kg/m2) -0.13 ± 0.7 0.05 ± 0.8 0.37
Education (%)
Illiterate 3 (10.7) 4 (14.3)
Elementary 11 (39.3) 10 (35.7)
Intermediate 14 (50) 13 (46.4) 0.74†
Diploma 0 (0) 1 (3.6)
Marital status (%)
Single 12 (42.9) 10 (35.7)
Married 7 (25) 6 (21.4) 0.70†
Widow/Divorced 9 (32.1) 12 (42.9)
Job (%)
Unemployed 24 (85.7) 21 (75)
Employed 0 (0) 2 (7.1) 0.31†
Others 4 (14.3) 5 (17.9)
Use of other drugs (%)
None 23 (82.2) 19 (67.8)
Sedative-Hypnotic 2 (7.1) 5 (17.9) 0.40†
Antidepressants 3 (10.7) 4 (14.3)
Age of the ﬁrst MA experience 32 ± 7.8 32.6 ± 8.6 0.77
Dose of MA use (g/week) 0.59 ± 0.4 0.47 ± 0.4 0.29
Frequency of MA use (week) 3.2 ± 1.4 2.7 ± 1.4 0.17
Duration of MA use (y) 2.2 ± 1.0 2.5 ± 1.1 0.33
Methadone dose (mL/d) 17.3 ± 4.4 18.9 ± 5.4 0.23
Duration of MMT (y) 5.5 ± 2.0 6.1 ± 2.1 0.28
a Data are mean±SDs.
b Obtained from independent t-test.
† Obtained from Pearson Chi-square test.
Table 2
The eﬀect of quetiapine on mental health, and cognitive function parameters in methadone maintenance treatment patients.
Variables Placebo group (n=28) Quetiapine group (n=28) Diﬀerence in outcome measures between quetiapine and placebo treatment groupsa
Baseline Week 8 Baseline Week 8 b (95% CI) Pb
BAI 16.4 ± 4.2 16.8 ± 4.0 18.2 ± 6.4 17.2 ± 5.5 -0.31 (-2.81, 2.17) 0.79
BDI 20.1 ± 6.7 20.1 ± 8.7 20.5 ± 5.6 17.1 ± 5.5 -3.94 (-7.73, -0.16) 0.04
PSQI 6.3 ± 1.9 6.4 ± 2.3 6.7 ± 2.2 4.3 ± 1.6 -2.18 (-2.89, -1.47) <0.001
IGT 26.4 ± 5.1 27.5 ± 4.1 25.89± 4.6 24.1 ± 6.1 -2.70 (-4.69, -0.71) 0.009
TMT subscales
TMT-A 20.6 ± 3.0 21.8 ± 4.0 21.5 ± 2.4 20.8 ± 2.5 -1.07 (-2.77, -0.62) 0.20
TMT-B 51.7 ± 6.4 50.7 ± 4.9 50.6 ± 5.4 49.3 ± 4.9 -1.45 (-4.27, 1.35) 0.30
Verbal ﬂuency test (FAS test)
Numbers of total words 32.8 ± 3.2 33.9 ± 3.2 33.7 ± 2.9 37.4 ± 3.4 3.04 (1.24, 4.85) 0.001
DGSP
DGSP-straight 8.9 ± 1.5 9.3 ± 1.3 9.1 ± 1.7 9.8 ± 1.2 0.40 (-0.18, 0.98) 0.17
DGSP-reverse 7.9 ± 1.1 7.8 ± 1.4 8.3 ± 1.0 10.7 ± 0.8 2.80 (2.13, 3.47) 0.001
Data are mean± SDs.
a ″Outcome measures" refers to the change in values of measures of interest between baseline and week 8. b [diﬀerence in the mean outcomes measures between
treatment groups (quetiapine group =1 and placebo group =0)].
b Obtained from multiple regression model (adjusted for baseline values age and baseline weight).
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2.8. Anthropometric scale
Anthropometric measures of cases were established using a standard




Beck Depression Inventory (BDI) was assessed using a self-compiled
questionnaire (Buysse et al., 1989). Quality of sleep was determined
using Pittsburgh Sleep Quality Index (PSQI) (Beck et al., 1961). Anxiety
parameters measured by Beck Anxiety Inventory (BAI) that developed
by Beck et al. (1988) to determine the frequency of anxiety scales in
young people and adults.
2.9.2. Cognitive functions
Trail Making Test (TMT) is normally administered in two sub-
components that are known as TMT-A and TMT-B (Lamberty et al.,
1994; Stuss et al., 2001). TMT measures several cognitive tasks (e.g.,
Fig. 2. Change (means± SDs) in BAI, BDI and PSQI score in patients MA abuse under MMT receiving quetiapine and placebo.
P value was obtained from independent t-test. N=28 in each group.
Fig. 3. Change (means± SDs) in IGT score, TMT-A and TMT-B scales in patients MA abuse under MMT receiving quetiapine and placebo.
P value was obtained from independent t-test. N=28 in each group.
Fig. 4. Change (means± SDs) in FAS test, DGSP-straight and DGSP-Reverse in patients MA abuse under MMT receiving quetiapine and placebo.
P value was obtained from independent t-test. N=28 in each group.
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visual search and scanning, attention, sequencing and shifting, ab-
straction, cognitive ﬂexibility and psychomotor speed)
(Salthouse, 2011). TMT is normally administered using two sub-com-
ponents which are found as TMT-A and TMT-B. In TMT-A, the subjects
is accessible with encircled numbers from 1 to 25 randomly distributed
on a sheet of paper, and they are instructed to link the numbers in
ascending order (i.e., 1-2-3…) applying a pencil or pen. In TMT-B is
known as a second sheet which is included both letters and encircled
numbers and that the subjects should link in alternating ascending
order (i.e., 1-A-2-B-…). Task performance in each section is common
quantiﬁed by obtaining the completion time, with TMT-B taking longer
to complete. IOWA gambling task (IGT) is a useful tool for analyzing the
individuals’ decision making process. The participants were faced with
four cards. The ﬁrst two cards oﬀer higher prizes but sometimes give
the participants some negative points as well. On the other side, the last
two cards oﬀer less amounts of money but their probability of losing
was far less than two others (Businelle et al., 2008; Turnbull et al.,
2014). Short-term auditory memory was measures by Digits spans
backwards in Wechsler intelligence Scale (DGSP). The patients read a
list of three to nine digits calmly and loudly, and the subject should read
them in the same way after listening to each list. This test, which is one
of the most commonly used index of intelligence, requires that the
subject reciprocate some of the lists of read digits in the same way and
others. In the ﬁrst case, memory is for direct cultivars, and in the second
case, memory for the invertible variables is measured (Jasinski et al.,
2011; Pilgrim et al., 1999). The Verbal Fluency Test (FAS test), a subtest
of the Neurosensory Center Comprehensive Examination for Aphasia
(Crockett, 1977) is a measure of phonemic word ﬂuency, which is a
type of verbal ﬂuency. It assesses phonemic ﬂuency by requesting an
individual to orally produce as several words as possible that begin with
the letters F, A, and S within a prescribed time frame, usually 1min.
2.10. Sample size
Sample size was calculated based on the primary outcomes and
using the results of a prior study (Katzman et al., 2011) in which s1, s2,
μ1 and μ2 of the anxiety score in the placebo and quetiapine groups
were respectively 0.24, 0.21, 1.90, and 1.76. Type one (α) and type two
errors (β) were deﬁned as 0.05, and 0.20, having the study power of
80%, the sample size was estimated at 22 subjects for each group; based
on allowing for dropouts in each group, the ﬁnal sample size was
considered to be 30 participants in each group.
2.11. Statistical analysis
The normality of data distribution was assessed using Kolmogorov-
Smirnov test. Independent sample t-test was applied to determine the
diﬀerences in anthropometric measures and dietary intakes between
the two intervention groups. Multiple linear regression models were
used to assess treatment eﬀects on study outcomes after adjusting for
confounding variables including the baseline values of outcomes as well
as age and BMI at baseline. The eﬀect sizes were reported as the mean
diﬀerences via 95% conﬁdence intervals. Bootstrapping was also used
as a sensitivity analysis of conﬁdence intervals and inverse probability
weighting was used to account for loss-to-follow-up, but the results did
not change substantially. The P-values of<0.05 were considered sta-
tistically signiﬁcant.
3. Results
Two participants in the treatment and placebo groups dropped out
for personal reasons. Eventually, 56 patients [quetiapine (n=28) and
placebo (n=28)] completed the study (Fig. 1). The compliance rate in
our trial was high; more than 90% of capsules were administration
during the trial in both groups. No serious side eﬀects were reported
following the administration of quetiapine in patients MA abuse.
Although, grade 1 adverse events were reported in 7 cases in the que-
tiapine group [headache (n=3), drowsiness (n=3) and vertigo
(n=1)], no patients was excluded in this trial.
Mean age, BMI, weight, height, education, marital status, job, use of
other drugs, age of the ﬁrst MA experience, dose of MA use, frequency
of MA use, duration of MA use, methadone dose and duration of MMT
were not signiﬁcantly diﬀerent among quetiapine and control groups
(Table 1).
Quetiapine signiﬁcantly reduced BDI (b -3.94; 95% CI, -7.73, -0.16;
P=0.04) and PSQI (b -2.18; 95% CI, -2.89, -1.47; P < 0.001)
(Table 2).
Patients who received quetiapine had a signiﬁcant reduction in IGT
(b -2.70; 95% CI, -4.69, -0.71; P=0.009), and signiﬁcant increases in
Verbal Fluency Test (b 3.04; 95% CI, 1.24, 4.85; P=0.001), DGSP-
Reverse (b 2.80; 95% CI, 2.13, 3.47; P=0.001) (Table 2). Quetiapine
administration did not change other cognitive functions and mental
health parameters. Changes in BDI score, BAI score, PSQI score, IGT
score, TMT-A scales, TMT-B scales, FAS test, DGSP-Straight and DGSP-
Reverse score in patients MA abuse under MMT receiving quetiapine
and placebo are presented in Figs. 2–4.
4. Discussion
We evaluated the impacts of quetiapine administration for 8 weeks
on mental health parameters and cognitive functions in patients with
MA abuse under MMT. Our study demonstrated that administration
quetiapine for 8 weeks, compared with the placebo, improved BDI,
PSQI, IGT, FAS, DGSP-Reverse, but did not aﬀect BAI, TMT subscales,
and DGSP-Straight. Based on these ﬁndings, quetiapine may an ap-
propriate adjunct therapy for patients with MA and opioid co-abuse. To
our knowledge, this trial for the ﬁrst time evaluated the eﬀects of
quetiapine on mental health parameters and cognitive functions of
patients with MA with MA and opioid co- abuse.
4.1. Eﬀects on mental health
Patients with MA abuse under MMT are susceptible to many psy-
chological disturbances, such as sleep, anxiety, and depression (Ghaderi
et al., 2017a; Glasner-Edwards et al., 2009; Glasner-Edwards et al.,
2010; Mahoney et al., 2014). We found that quetiapine intake to pa-
tients MA abuse in MMT for 8 weeks improved depression and sleep
indexes, yet did not aﬀect anxiety indices. It should be considered that
in the present report, subjects were matched based on dosage of me-
thadone. However, we think that this can not aﬀect on our results be-
cause subjects in both non-intervention and intervention were receiving
methadone. Hence, the considered pharmacological impacts on de-
pression and sleep can be due to receiving quetiapine. This must be
taken into account in the understanding of our results. Several studies
have investigated the eﬀects of quetiapine on mental health parameters
in participants without MA abuse under MMT, though the results are
controversial. Baune (2008), observed that quetiapine intake (range
50–300mg/day) for 8 weeks can play a signiﬁcant role in the man-
agement of major depressive disorder (MDD) and general anxiety. In
addition, taking quetiapine (average 153mg/day) for 28 day by pa-
tients with coexisting substance dependence disorders had beneﬁcial
eﬀects on sleep, anxiety, and depression (Sattar et al., 2004).
Monnelly et al. (2004) also found that quetiapine at a dosage of
20–200mg/day improved sleep disturbance in alcohol dependence. In
another study, quetiapine administration (ﬂexible doses, 50–800mg/
day) for 16 weeks had signiﬁcant eﬃcacy on psychiatric symptoms
(Martinotti et al., 2008). The impact of quetiapine in treating psycho-
logical symptoms disturbance leads to the view that it is a multi-
functional psychoactive drug. It's a wide range of eﬀect is likely due to
its ability to alter systems of noradrenergic, serotonergic and dopami-
nergic and its eﬃcacy appear to be mediated via the actions of nor-
quetiapine and quetiapine (Altamura et al., 2012).
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4.2. Eﬀects on cognitive function
MA abuses under MMT were associated with increased cognitive
disturbance (Potvin et al., 2018; Wang et al., 2017). Our study sup-
ported that consuming quetiapine for 8 weeks by patients with MA
abuse under MMT signiﬁcantly improved IGT, FAS, and DGSP-Reverse,
but did not aﬀect TMT subscales, and DGSP-Straight. Although data
presenting the eﬀects of quetiapine on cognitive function in MA abusers
under MMT are scarce, the eﬀects of quetiapine on cognitive function in
other patients have been evaluated. In an animal study by
He et al. (2006), it was shown that the intake of quetiapine had ame-
liorated the eﬀects of MA on cognitive and memory impairment in rats.
Also, Purdon et al. (2001) found that quetiapine intake were associated
with a better general cognitive, verbal reasoning and ﬂuency after 6-
month treatment. Furthermore, receiving quetiapine (mean dose was
350±213mg/days) for 12 weeks was related to improves cognitive
function and positive scale in patients episode psychosis (Urben et al.,
2012). Moreover, the enhancement of cognitive function after using
quetiapine have been considered to be higher than those observed in
treatment resistant patients who received clozapine (Buchanan et al.,
1994). However, quetiapine compared to olanzapine did not inﬂuence
cognitive, learning and memory in an adolescent population
(Robles et al., 2011). The absence of signiﬁcant eﬀect of quetiapine on
TMT subscales, and DGSP-Straight might be explained through using
diﬀerent trial designs, diﬀerent dosages of quetiapine used as well as
diﬀerent characteristics of participants. The eﬀects of quetiapine on
cognitive function maybe mediated through inducing acetylcholine
release (Ichikawa et al., 2002; Samiei et al., 2016). Acetylcholine is
found that a very important neurotransmitter which is related to
learning and memory consolidation. It has been showed that the in-
creasing concentrations of acetylcholine could lead to the improvement
of memory. Moreover, quetiapine is able to reduce the immobilization
stress-induced via modulating BDNF expression. And this drug enables
to enhance neuroplasticity though over expression of BDNF
(Fumagalli et al., 2004). BDNF prompts the induced neuronal death by
METH (Matsuzaki et al., 2004) that has a critical role in the related
memory parts (i.e., social recognition memory and spatial memory)
(Broad et al., 2002). Future evidences need to evaluate the beneﬁcial
eﬀects of quetiapine related genes (e.g. BDNF) in the METH-induced
memory disturbence and neuro-toxicity.
The present report is associated with some limitations such as the
longer-term intervention is needed to illustrate more beneﬁts or adverse
eﬀects of quetiapine. Also, we were not able to assess the craving in
subjects with methamphetamine abuse under MMT. Thus, it seems that
more assessment on craving caused by quitting is needed in further
studies. In addition, a number of patients complained of quetiapine side
eﬀects, such as headache, vertigo and drowsiness, which this should be
considered in the interpretation of our ﬁndings.
5. Conclusions
Finally, we found that administration quetiapine for 8 weeks in
patients with MA and opioid co-abuse under MMT improved BDI, PSQI,
IGT, FAS, DGSP-Reverse, yet did not aﬀect BAI, TMT subscales, and
DGSP-Straight. Further evidence are needed to show the relative impact
of quetiapine on MA and opioid co- abuse under MMT and perhaps
larger samples should be used. The combination therapy of quetiapine
and methadone in opioid withdrawal protocols could be also in-
troduced for increasing the quality of life and decrease the risk of MA
abuse.
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